夜间 WASO

早晨嗜睡

白天警觉性和工作能力

1. [1]American Psychiatric Association Diagnostic and statistical manual of mental disorders: DSM-5 (fifth ed.) (2013) Arlington, VA, US

   Google Scholar

2. [2]M.J. Sateia International classification of sleep disorders Chest, 146 (5) (2014), pp. 1387-1394

   View PDFView articleCrossrefView in ScopusGoogle Scholar

3. [3]D. Riemann, C.A. Espie, E. Altena, et al. The European Insomnia Guideline: an update on the diagnosis and treatment of insomnia 2023

   J Sleep Res, 32 (6) (2023), Article e14035

   View in ScopusGoogle Scholar

4. [4]C.M. Morin, B. Bei, B. Bjorvatn, et al.

   World Sleep Society international sleep medicine guidelines position statement endorsement of “behavioral and psychological treatments for chronic insomnia disorder in adults: an American Academy of sleep medicine clinical practice guidelines”

   Sleep Med, 109 (2023), pp. 164-169

   View PDFView articleView in ScopusGoogle Scholar

5. [5]J.D. Edinger, J.T. Arnedt, S.M. Bertisch, et al.

   Behavioral and psychological treatments for chronic insomnia disorder in adults: an American Academy of Sleep Medicine clinical practice guideline

   J Clin Sleep Med., 17 (2) (2021), pp. 255-262

   View at publisherCrossrefView in ScopusGoogle Scholar

6. [6]S. Wilson, K. Anderson, D. Baldwin, et al.

   British Association for Psychopharmacology consensus statement on evidence-based treatment of insomnia, parasomnias and circadian rhythm disorders: an update

   J Psychopharmacol, 33 (2019), Article 026988111985534

   Google Scholar

7. [7]R.P. Rosenberg

   Sleep maintenance insomnia: strengths and weaknesses of current pharmacologic therapies

   Ann Clin Psychiatr, 18 (1) (2006), pp. 49-56

   View at publisherCrossrefView in ScopusGoogle Scholar

8. [8]E. Mignot

   Physiology. The perfect hypnotic?

   Science, 340 (6128) (2013), pp. 36-38

   View at publisherCrossrefView in ScopusGoogle Scholar

9. [9]J.M. Uslaner, W.J. Herring, P.J. Coleman

   The discovery of suvorexant: lessons learned that can be applied to other CNS drug development efforts

   ACS Pharmacol Transl Sci, 3 (1) (2020), pp. 161-168

    

   View at publisher

   CrossrefView in ScopusGoogle Scholar

    

10. [10]R. Rosenberg, P. Murphy, G. Zammit, et al.

    Comparison of lemborexant with placebo and zolpidem tartrate extended release for the treatment of older adults with insomnia disorder: a phase 3 randomized clinical trial

    JAMA Netw Open, 2 (2019), Article e1918254

     

    View at publisher

    CrossrefGoogle Scholar

     

11. [11]U.S Food and Drug Administration

    United States prescribing information (USPI): belsomra (suvorexant)

    Available at:

    https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/204567s007lbl.pdf (2014)

    Google Scholar

12. [12]W.J. Herring, K.M. Connor, N. Ivgy-May, et al.

    Suvorexant in patients with insomnia: results from two 3-month randomized controlled clinical trials

    Biol Psychiatry, 79 (2) (2016), pp. 136-148

    View PDFView articleView in ScopusGoogle Scholar

13. [13]Center for Drug Evaluation and Research

    Suvorexant (belsomra) for insomnia. Application number: 204569Orig1s000. Summary review

    Available at:

    https://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/204569Orig1s000SumR.pdf (2014)

    Google Scholar

14. [14]U.S Food and Drug Administration

    United States prescribing information (USPI): dayvigo (lemborexant)

    Available at:

    https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/212028s000lbl.pdf (2019)

    Google Scholar

15. [15]U.S Food and Drug Administration

    QUVIVIQ prescribing information

    Idorsia Pharmaceuticals US Inc (2022)

    Google Scholar

16. [16]European Medicines Agency

    QUIVIVIQ - summary of product characteristics

    (2022)

    Google Scholar

17. [17]C. Muehlan, S. Brooks, R. Zuiker, et al.

    Multiple-dose clinical pharmacology of ACT-541468, a novel dual orexin receptor antagonist, following repeated-dose morning and evening administration

    Eur Neuropsychopharmacol, 29 (7) (2019), pp. 847-857

    View PDFView articleView in ScopusGoogle Scholar

18. [18]E. Mignot, D. Mayleben, I. Fietze, et al.

    Safety and efficacy of daridorexant in patients with insomnia disorder: results from two multicentre, randomised, double-blind, placebo-controlled, phase 3 trials

    Lancet Neurol, 21 (2) (2022), pp. 125-139

    View PDFView articleView in ScopusGoogle Scholar

19. [19]A. Hamlett, L. Ryan, P. Serrano-Trespalacios, et al.

    Mixed models for assessing correlation in the presence of replication

    J Air Waste Manag Assoc, 53 (4) (2003), pp. 442-450

     

    View at publisher

    CrossrefView in ScopusGoogle Scholar

     

20. [20]Huang Q. Proc mixed : calculate correlation coefficients in the presence of repeated measurements. 2019. Available at: https://www.pharmasug.org/proceedings/2019/ST/PharmaSUG-2019-ST-321.pdf.

    Google Scholar

21. [21]S.C. Bolge, V.N. Joish, R. Balkrishnan, et al.

    Burden of chronic sleep maintenance insomnia characterized by nighttime awakenings

    Popul Health Manag, 13 (1) (2010), pp. 15-20

    View at publisherCrossrefView in ScopusGoogle Scholar

22. [22]I. Bjorøy, V.A. Jørgensen, S. Pallesen, et al.

    The prevalence of insomnia subtypes in relation to demographic characteristics, anxiety, depression, alcohol consumption and use of hypnotics

    Front Psychol, 11 (2020), p. 527

    View in ScopusGoogle Scholar

23. [23]T. Di Marco, T.E. Scammell, M. Meinel, et al.

    Number, duration, and distribution of wake bouts in patients with insomnia disorder: effect of daridorexant and zolpidem

    CNS Drugs, 37 (7) (2023), pp. 639-653

    CrossrefView in ScopusGoogle Scholar

24. [24]T. Roth, T.A. Roehrs

    Issues in the use of benzodiazepine therapy

    J Clin Psychiatry, 53 (Suppl) (1992), pp. 14-18

    View in ScopusGoogle Scholar

25. [25]D.A. Dornbierer, F. Yerlikaya, R. Wespi, et al.

    A novel bedtime pulsatile-release caffeine formula ameliorates sleep inertia symptoms immediately upon awakening

    Sci Rep, 11 (1) (2021), Article 19734

    View in ScopusGoogle Scholar

26. [26]R. Robbins, S.F. Quan, D. Buysse, et al.

    A nationally representative survey assessing restorative sleep in US adults

    Front Sleep, 1 (2022)

    Google Scholar

27. [27]S.J. Kim, S. Kim, S. Jeon, et al.

    Factors associated with fatigue in patients with insomnia

    J Psychiatr Res, 117 (2019), pp. 24-30

    View PDFView articleGoogle Scholar

28. [28]E. Fortier-Brochu, S. Beaulieu-Bonneau, H. Ivers, et al.

    Relations between sleep, fatigue, and health-related quality of life in individuals with insomnia

    J Psychosom Res, 69 (5) (2010), pp. 475-483

    View PDFView articleView in ScopusGoogle Scholar

29. [29]V. Svetnik, E. Snyder, P. Tao, et al.

    How well can a large number of polysomnography sleep measures predict subjective sleep quality in insomnia patients?

    Sleep Med, 67 (2019)

    Google Scholar

30. [30]S.J. McCarter, P.T. Hagen, E.K. St Louis, et al.

    Physiological markers of sleep quality: a scoping review

    Sleep Med Rev, 64 (2022), Article 101657

    View PDFView articleView in ScopusGoogle Scholar

31. [31]L. Rezaie, A.D. Fobian, W.V. McCall, et al.

    Paradoxical insomnia and subjective-objective sleep discrepancy: a review

    Sleep Med Rev, 40 (2018), pp. 196-202

    View PDFView articleView in ScopusGoogle Scholar

32. [32]K. Trimmel, H.G. Eder, M. Böck, et al.

    The (mis)perception of sleep: factors influencing the discrepancy between self-reported and objective sleep parameters

    J Clin Sleep Med : JCSM : Off. Pub. Am. Academy Sleep Med., 17 (5) (2021), pp. 917-924

    View at publisherCrossrefView in ScopusGoogle Scholar

33. [33]C.L. Drake, R.D. Hays, R. Morlock, et al.

    Development and evaluation of a measure to assess restorative sleep

    J Clin Sleep Med, 10 (7) (2014), pp. 733-741

    741a-741e

    View at publisherCrossrefView in ScopusGoogle Scholar

达利雷生

Quviviq®